Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/2599
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | COCKS, K. | - |
dc.contributor.author | KING, M. T. | - |
dc.contributor.author | VELIKOVA, G. | - |
dc.contributor.author | CASTRO JR., G. de | - |
dc.contributor.author | ST-JAMES, M. Martyn | - |
dc.contributor.author | FAYERS, P. M. | - |
dc.contributor.author | BROWN, J. M. | - |
dc.date.accessioned | 2013-10-02T19:36:06Z | - |
dc.date.available | 2013-10-02T19:36:06Z | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | EUROPEAN JOURNAL OF CANCER, v.48, n.11, p.1713-1721, 2012 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/2599 | - |
dc.description.abstract | Aim: To use published literature and experts' opinion to investigate the clinical meaning and magnitude of changes in the Quality of Life (QOL) of groups of patients measured with the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Methods: An innovative method combining systematic review of published studies, expert opinions and meta-analysis was used to estimate large, medium, and small mean changes over time for QLQ-C30 scores. Results: Nine hundred and eleven papers were identified, leading to 118 relevant papers. One thousand two hundred and thirty two mean changes in QOL over time were combined in the meta-analysis, with timescales ranging from four days to five years. Guidelines were produced for trivial, small, and medium size classes, for each subscale and for improving and declining scores separately. Estimates for improvements were smaller than respective estimates for declines. Conclusions: These guidelines can be used to aid sample size calculations and interpretation of mean changes over time from groups of patients. Observed mean changes in the QLQ-C30 scores are generally small in most clinical situations, possibly due to response shift. Careful consideration is needed when planning studies where QOL changes over time are of primary interest; the timing of follow up, sample attrition, direction of QOL changes, and subscales of primary interest are key considerations. | - |
dc.description.sponsorship | Cancer Research UK | - |
dc.description.sponsorship | Cancer Research UK [C7852/A5653] | - |
dc.description.sponsorship | UICC ICRETT fellowship | - |
dc.language.iso | eng | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.relation.ispartof | European Journal of Cancer | - |
dc.rights | restrictedAccess | - |
dc.subject | Statistical data interpretation | - |
dc.subject | Quality of life | - |
dc.subject | Longitudinal studies | - |
dc.subject | Meaningful difference | - |
dc.subject | Minimally important difference | - |
dc.subject | Sample size | - |
dc.subject.other | randomized controlled-trials | - |
dc.subject.other | eortc qlq-c30 | - |
dc.subject.other | population | - |
dc.title | Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 | - |
dc.type | article | - |
dc.rights.holder | Copyright ELSEVIER SCI LTD | - |
dc.identifier.doi | 10.1016/j.ejca.2012.02.059 | - |
dc.identifier.pmid | 22418017 | - |
dc.subject.wos | Oncology | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | COCKS, K.:Univ Leeds, Clin Trials Res Unit, Leeds LS2 9JT, W Yorkshire, England | - |
hcfmusp.author.external | KING, M. T.:Univ Sydney, Psychooncol Cooperat Res Grp, Qual Life Off, Sydney, NSW 2006, Australia | - |
hcfmusp.author.external | VELIKOVA, G.:Univ Leeds, Leeds Inst Mol Med, St Jamess Inst Oncol, Leeds, W Yorkshire, England | - |
hcfmusp.author.external | ST-JAMES, M. Martyn:Univ Leeds, Clin Trials Res Unit, Leeds LS2 9JT, W Yorkshire, England | - |
hcfmusp.author.external | FAYERS, P. M.:Univ Aberdeen, Sch Med & Dent, Inst Appl Hlth Sci, Aberdeen AB9 1FX, Scotland; NTNU, Fac Med, Dept Canc Res & Mol Med, Trondheim, Norway | - |
hcfmusp.author.external | BROWN, J. M.:Univ Leeds, Clin Trials Res Unit, Leeds LS2 9JT, W Yorkshire, England | - |
hcfmusp.description.beginpage | 1713 | - |
hcfmusp.description.endpage | 1721 | - |
hcfmusp.description.issue | 11 | - |
hcfmusp.description.volume | 48 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | WOS:000305781300016 | - |
hcfmusp.origem.id | 2-s2.0-84862771595 | - |
hcfmusp.publisher.city | OXFORD | - |
hcfmusp.publisher.country | ENGLAND | - |
hcfmusp.relation.reference | Cella D, 2002, QUAL LIFE RES, V11, P207, DOI 10.1023/A:1015276414526 | - |
hcfmusp.relation.reference | Cocks K, 2011, EBIG EXPERT REV MANU | - |
hcfmusp.relation.reference | Cocks K, 2011, J CLIN ONCOL, V29, P89, DOI 10.1200/JCO.2010.28.0107 | - |
hcfmusp.relation.reference | Cocks K, 2008, EUR J CANCER, V44, P1793, DOI 10.1016/j.ejca.2008.05.008 | - |
hcfmusp.relation.reference | Cooper H, 2009, HDB RES SYNTHESIS ME | - |
hcfmusp.relation.reference | Fayers PM, 2001, EUR J CANCER, V37, P1331, DOI 10.1016/S0959-8049(01)00127-7 | - |
hcfmusp.relation.reference | Hjermstad MJ, 1998, J CLIN ONCOL, V16, P1188 | - |
hcfmusp.relation.reference | King MT, 2001, QUAL LIFE RES, V10, P278 | - |
hcfmusp.relation.reference | King Madeleine T, 2010, Patient Relat Outcome Meas, V1, P119, DOI 10.2147/PROM.S10621 | - |
hcfmusp.relation.reference | King MT, 2010, J CLIN EPIDEMIOL, V63, P270, DOI 10.1016/j.jclinepi.2009.05.001 | - |
hcfmusp.relation.reference | King MT, 1996, QUAL LIFE RES, V5, P555, DOI 10.1007/BF00439229 | - |
hcfmusp.relation.reference | Klee M, 1997, QUAL LIFE RES, V6, P27 | - |
hcfmusp.relation.reference | Lipsey M.W., 2001, PRACTICAL METAANALYS | - |
hcfmusp.relation.reference | Maringwa J, 2011, ANN ONCOL, V22, P2107, DOI 10.1093/annonc/mdq726 | - |
hcfmusp.relation.reference | Maringwa JT, 2011, SUPPORT CARE CANCER, V19, P1753, DOI 10.1007/s00520-010-1016-5 | - |
hcfmusp.relation.reference | Michelson H, 2000, ACTA ONCOL, V39, P477 | - |
hcfmusp.relation.reference | Osoba D, 1998, J CLIN ONCOL, V16, P139 | - |
hcfmusp.relation.reference | Ringash J, 2007, CANCER, V110, P196, DOI 10.1002/cncr22799 | - |
hcfmusp.relation.reference | Schwarz R, 2001, EUR J CANCER, V37, P1345, DOI 10.1016/S0959-8049(00)00447-0 | - |
hcfmusp.relation.reference | Sprangers MAG, 1996, CANCER TREAT REV, V22, P55, DOI 10.1016/S0305-7372(96)90064-X | - |
hcfmusp.relation.reference | Wang MC, 1999, INTEGRATING RESULTS | - |
dc.description.index | MEDLINE | - |
hcfmusp.lim.ref | 2012 | - |
hcfmusp.citation.scopus | 335 | - |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - HC/ICESP Artigos e Materiais de Revistas Científicas - LIM/24 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_CASTRO JR._Evidence_based_guidelines_for_interpreting_change_scores_for_2012.PDF Restricted Access | publishedVersion (English) | 444.85 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.